AKAN · Akanda Corp. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q4 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q4 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | $2.12M | - | - | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | - | - | - | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - |
| EPS - Basic | - | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q4 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q4 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.53M | $3.84M | $443.3K | $93.9K | $228.8K | $3.93M | - | $3.50M | $13.5K | $819.6K |
| Accounts Receivable | $4.1K | $370.5K | $311.7K | $284.5K | $1.24M | $726.9K | - | $242.4K | - | - |
| Inventory | - | - | - | $1.29M | $1.06M | $895.8K | - | - | $611 | - |
| Accounts Payable | $2.20M | $2.98M | $3.76M | $6.01M | $7.14M | $4.49M | - | $680.3K | $183.9K | - |
| Current Assets | $3.57M | $5.06M | $7.61M | $1.81M | $3.82M | $6.94M | - | $3.98M | $127.6K | - |
| Total Assets | $6.22M | $7.91M | $9.97M | $8.84M | $39.00M | $43.48M | - | $8.05M | $4.27M | - |
| Current Liabilities | $2.84M | $3.64M | $5.40M | $10.17M | $9.35M | $6.27M | - | $8.27M | $2.73M | - |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $2.91M | $3.64M | $5.40M | $12.67M | $12.10M | $8.84M | - | $10.25M | $9.31M | - |
| Stockholders' Equity | $3.30M | $4.28M | $4.57M | ($3.83M) | $26.90M | $34.64M | - | ($2.20M) | ($5.03M) | ($2.90M) |
| Retained Earnings | ($58.25M) | ($57.46M) | ($56.05M) | ($53.36M) | ($21.09M) | ($12.02M) | - | ($13.29M) | ($5.16M) | - |
Cash Flow
| Line item | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q4 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q4 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q4 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q4 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | - | - | - | - | - | - | - | - | - |
| Return on equity | - | - | - | - | - | - | - | - | - | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.25 | 1.39 | 1.41 | 0.18 | 0.41 | 1.11 | - | 0.48 | 0.05 | - |
| Quick ratio | 1.25 | 1.39 | 1.41 | 0.05 | 0.30 | 0.96 | - | 0.48 | 0.05 | - |
| Cash ratio | 0.89 | 1.06 | 0.08 | 0.01 | 0.02 | 0.63 | - | 0.42 | 0.00 | - |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.88 | 1.85 | 2.18 | -2.31 | 1.45 | 1.26 | - | -3.65 | -0.85 | - |
| Liabilities / Assets | 0.47 | 0.46 | 0.54 | 1.43 | 0.31 | 0.20 | - | 1.27 | 2.18 | - |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Net income growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -27.8% | - | - | - | - | - | - | 56.3% | -73.2% | -97.9% |
Peer comparison
Same SIC group: Medicinal Chemicals & Botanical Products
Comparing AKANDA CORP. against the 5 most active filers in the same SIC group.